Cystic Fibrosis (CF)

Rare Disease·MeSH: Cystic Fibrosis

Prevalence

4.0 / 100K

Incidence

3.5 / 100K/yr

12 drugs in development·6 companies·7 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
cayston	GILEAD SCIENCES, INC. (GILD)
kalydeco	VERTEX PHARMACEUTICALS INC / MA (VRTX)
trikafta	VERTEX PHARMACEUTICALS INC / MA (VRTX)

Phase 2(4)

Drug	Company
adrulipase	GridAI Technologies Corp. (GRDX)
sion-2851	Sionna Therapeutics, Inc. (SION)
sion-3067	Sionna Therapeutics, Inc. (SION)
sion-719	Sionna Therapeutics, Inc. (SION)

Phase 1(4)

Drug	Company
CB-280	Calithera Biosciences, Inc. (CALA)
sion-109	Sionna Therapeutics, Inc. (SION)
sion-2222	Sionna Therapeutics, Inc. (SION)
sion-451	Sionna Therapeutics, Inc. (SION)

Phase 4(1)

Drug	Company
elexacaftor / ivacaftor / tezacaftor	GH Research PLC (GHRS)

BioSniper tracks 12 drugs in development for Cystic Fibrosis (CF) across 6 companies.

There are 7 clinical trials targeting Cystic Fibrosis (CF) tracked by BioSniper.

The estimated prevalence of Cystic Fibrosis (CF) is approximately 4.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.